Liquid biopsy study halted: did it help guide cancer care?
NCT ID NCT06290856
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if a simple blood test (liquid biopsy) could help doctors make better treatment decisions for people with advanced cancers of the colon, pancreas, or bile duct. Researchers planned to enroll about 130 participants but stopped early with only 16 enrolled. The main goal was to check if the test results actually led to changes in diagnosis or treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oslo university Hospital
Oslo, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- A new test could reveal how radiation affects the liver
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?